SIRT6 抗体 (pSer338)
(1 reference)Quick Overview for SIRT6 抗体 (pSer338) (ABIN712481)
抗原
See all SIRT6 抗体适用
宿主
克隆类型
标记
应用范围
-
-
抗原表位
- pSer338
-
交叉反应
- 人
-
纯化方法
- Purified by Protein A.
-
免疫原
- KLH conjugated synthetic phosphopeptide derived from human SIRT6 around the phosphorylation site of Ser338
-
亚型
- IgG
-
-
anti-Sirtuin 6 (SIRT6) (AA 1-334) antibody
SIRT6 适用: 小鼠 WB, IHC, IP, ICC 宿主: 兔 Polyclonal unconjugated
anti-Sirtuin 6 (SIRT6) (AA 141-250) antibodySIRT6 适用: 人 ELISA, ICC, FACS 宿主: 小鼠 Monoclonal 2G1H1 unconjugated
anti-Sirtuin 6 (SIRT6) antibodySIRT6 适用: 人, 小鼠, 大鼠, 猴 WB, IP, IF 宿主: 小鼠 Monoclonal 6C9-D10-D3 unconjugated
anti-Sirtuin 6 (SIRT6) (Middle Region) antibodySIRT6 适用: 人, 大鼠, 犬, Cow WB, IP, ChIP 宿主: 兔 Polyclonal unconjugated
anti-Sirtuin 6 (SIRT6) (N-Term) antibodySIRT6 适用: 人, 小鼠, 大鼠, 犬, Cow, Pig, 豚鼠, 马 WB 宿主: 兔 Polyclonal unconjugated
anti-Sirtuin 6 (SIRT6) (AA 35-274) antibodySIRT6 适用: 人 WB, IHC, IP, ICC 宿主: 兔 Polyclonal unconjugated
anti-Sirtuin 6 (SIRT6) (C-Term) antibodySIRT6 适用: 人, 大鼠, 犬, Cow WB, IHC, IHC (p) 宿主: 兔 Polyclonal unconjugated
anti-Sirtuin 6 (SIRT6) (AA 56-105) antibodySIRT6 适用: 人, 小鼠, 犬, 猴, Pig, Bat, Hamster WB, IHC, IHC (p) 宿主: 兔 Polyclonal unconjugated
anti-Sirtuin 6 (SIRT6) (AA 141-250) antibodySIRT6 适用: 人 ELISA 宿主: 小鼠 Monoclonal 1D8 unconjugated
anti-Sirtuin 6 (SIRT6) (C-Term) antibodySIRT6 适用: 人 WB, IP 宿主: 兔 Polyclonal unconjugated
-
-
应用备注
-
WB 1:300-5000
ELISA 1:500-1000
IHC-P 1:200-400
IHC-F 1:100-500
IF(IHC-P) 1:50-200
IF(IHC-F) 1:50-200
IF(ICC) 1:50-200 -
限制
- 仅限研究用
-
-
-
状态
- Liquid
-
浓度
- 1 μg/μL
-
缓冲液
- 0.01M TBS( pH 7.4) with 1 % BSA, 0.02 % Proclin300 and 50 % Glycerol.
-
储存液
- ProClin
-
注意事项
- This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.
-
储存条件
- 4 °C,-20 °C
-
储存方法
- Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.
-
有效期
- 12 months
-
-
-
: "MDM2-mediated degradation of SIRT6 phosphorylated by AKT1 promotes tumorigenesis and trastuzumab resistance in breast cancer." in: Science signaling, Vol. 7, Issue 336, pp. ra71, (2014) (PubMed).
-
: "MDM2-mediated degradation of SIRT6 phosphorylated by AKT1 promotes tumorigenesis and trastuzumab resistance in breast cancer." in: Science signaling, Vol. 7, Issue 336, pp. ra71, (2014) (PubMed).
-
- SIRT6 (Sirtuin 6 (SIRT6))
-
别名
- SIRT6
-
背景
-
Synonyms: SIR2L6, NAD-dependent protein deacetylase sirtuin-6, Regulatory protein SIR2 homolog 6, SIR2-like protein 6, SIRT6
Background: NAD-dependent protein deacetylase. Has deacetylase activity towards histone H3K9Ac and H3K56Ac. Modulates acetylation of histone H3 in telomeric chromatin during the S-phase of the cell cycle. Deacetylates histone H3K9Ac at NF-kappa-B target promoters and may down-regulate the expression of a subset of NF-kappa-B target genes. Acts as a corepressor of the transcription factor HIF1A to control the expression of multiple glycolytic genes to regulate glucose homeostasis. Required for genomic stability. Regulates the production of TNF protein. Has a role in the regulation of life span (By similarity). Deacetylation of nucleosomes interferes with RELA binding to target DNA. May be required for the association of WRN with telomeres during S-phase and for normal telomere maintenance. Required for genomic stability. Required for normal IGF1 serum levels and normal glucose homeostasis. Modulates cellular senescence and apoptosis. On DNA damage, promotes DNA end resection via deacetylation of RBBP8. Has very weak deacetylase activity and can bind NAD(+) in the absence of acetylated substrate.
-
基因ID
- 51548
-
UniProt
- Q8N6T7
抗原
-
